We Leverage Our Collective Expertise For The Benefit Of Our Partners

Offices

New York – Paris

2

Team

15

Scientists

19

Hospital Partners

7

Forepont Capital Partners Investment Team

Eric M. Attias

CLOSE X

Eric M. Attias

Vision & Strategy

25 year experience

“Value creation comes from enabling key strategic players to work together. We have implemented that since 2014 and has led to tremendous value creation.”

Eric M. Attias launched Forepont Capital Partners in 2014. Eric sourced and invested in 5 high performing Medical ventures including San Diego-based decacorn SAMUMED, UK based revolutionary biotech company SiSaf and the French start-up BioSpeedia.

Since 2013, through his work in funding medical research as Chairman of the Neurogen Research Foundation, Eric developed partnerships and strong ties with CEOs and Top Managements of 8 of the biggest Pharmaceuticals companies, 10 of the most renowned hospitals and over 20 leading researchers and KOLs in Neurology.

In 2009 he co-founded Nexar Capital Group, backed by New York Private Equity firm Aquiline.

Nexar capital acquired both AAAM, European Alternative Asset Management business of insurance group Allianz and Ermitage Group from London based private Equity Firm Caledonia Partners.

After restructuring and integrating of both businesses, NEXAR controlled over $4 billion of Assets, in 2 years. Nexar was then acquired by Swiss Banking Group UBP in 2012.

In 2002 Eric established SG Asset Management business in New York. In four years, he built SGAM Inc from scratch to a 250 million USD annual revenue business with a staff of 60 and over $10 billion of Asset Under Management.

In 1999, In addition to his role in the Investment bank DrKW – Wasserstein Perella in New York, Eric was put in charge of its strategic venture fund DrKW OV Ltd.  He managed the 50-million USD Fintech ventures fund, sourced and seeded blockbusters like CapitalIQ and Creditex.

BS ENSAE (French grande école) in Applied Mathematics and data science
MS Mathematics at Paris Dauphine
MS in Econometrics at Paris II (Assas – Sorbonne)
Recipient of the Rothschild fellowship for advanced study and postgraduate research in mathematics at MIT.
Recipient of the bishofsheim scholarship in mathematics.
ABD in Applied mathematics and Data science. Thesis in Neural networks and genetic algorithms
MBA from Columbia University

Dr Ismail Kola

CLOSE X

Dr Ismail Kola

General Partner, US

Science Expert

“The opportunity to help Forepont and its uniquely creative ecosystem of companies really captured my imagination. Their focus on improving outcomes and efficiencies through any scientific platform makes this opportunity most appealing. Today we need to look to all aspects of science and breakdown the barriers between silos in order to solve some of our biggest medical challenges without the traditional costs to do so. Mentoring a new generation of science entrepreneurs will add to the pleasure of the challenge”.

Ismail Kola joined Forepont in early 2019 as a General Partner in charge of all scientific decisions.

He has led investments into biotech companies such as GPN Vaccines and Mobius BioMedical where he contributes his scientific expertise and his broad network as a board member and a scientific advisor to the firms.

Prior to Forepont, Ismail held several senior executive positions in the pharmaceutical industry as he has published 159 papers in top scientific journals which have been cited over 15,000 times and has brought 17 major medicines to market during his 20 year career in the pharmaceutical industry.

Ismail Kola was until 2018 the Chief Scientific Officer of UCB, the Belgium leading pharmaceutical company. He joined UCB from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation.

Ismail came to Schering-Plough from Merck, where he was Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid. He also chaired Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team.

In 1999, Ismail joined as Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for 15 years.

He holds a Ph.D. in Medicine from the University of Cape Town, South Africa

He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK.

He is a member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.

Julien Tizot

CLOSE X

Julien Tizot

General Partner, Europe

Execution & Investment

“Forepont’s unique philosophy truly unlocks value by accompanying entrepreneurs through every step of their growth. I am proud to work along ambitious founders as well as with talented partners throughout their journey, especially within the French Ecosystem.”

Julien joined Forepont in late 2018 as General Partner in charge of Europe. He seats on the board of the French companies bringing is financial and managerial expertise. Julien is also developing key partnerships with French and European institutions focusing on sourcing opportunities and strategic development.

Julien stepped in as the CEO of BioSpeedia SAS following the investment Forepont and powered the startup to become one of the leaders in the European rapid diagnostic test sector generating over 12 million dollars revenues within the first 6 months. Julien drove a strategic reindustrialization in France and won a significant mandate from the French government during the COVID crisis.

In 2015, Julien transitioned into Venture Capital in Switzerland and France including a role as the Venture Partner for France & Switzerland at Joyance Partners – one of the most active Corporate VC funds in the Silicon Valley focusing on healthcare and nutrition, leading many investments for the fund.

In 2009, Julien joined AG2R La Mondiale as the Head of Alternative Investment investing more than 2 billion dollars in a variety of strategies and was named several times as top French Institutional Investors.

In 2006, Julien started his career in the Silicon Valley where he launched his 1st venture Dynamic Fund Management.

Julien holds an MBA from Columbia Business School (Dean’s List) and London Business School. He also graduated from AMSE in France with an engineering degree in statistics and from Saint Mary’s College of California with an MSc in Finance.

In 2010, Julien finished valedictorian of the Certified International Investment Analyst exam and is since a member of the French SFAF.

Larry Rubin

CLOSE X

Larry Rubin

Partner, US

Technology Guru

“Applying AI and ML to neurodegenerative diseases has led to exponential progress in a short period of time demonstrating how efficient Forepont’s driving force can impact science and technology in complicated fields.”

Larry has been with Forepont since 2015 and has been the driving force as the co-founder and CTO of BeCareLink. Together with medical authorities, he created and developed the revolutionary platform that uses Machine Learning techniques to assess patient neurologic functions and clinically significant changes.

Larry, first, worked at Bell Laboratories where he was the co-inventor of a new type of neural network technology.

He, later, founded OuterCurve Technologies Inc which was funded by three public companies.

Larry is, also, the co-founder of Woman’s healthcare venture for detecting breast cancer that is in its 16th year of operation.

Larry has a Master of Philosophy in Computer Science, a MS in Computer Science and a MS in Mathematics from New York University.

Bruce Greenberg

CLOSE X

Bruce Greenberg

COO & CFO, US

25 years experience

Bruce has been Forepont’s CFO since the launch of the company. Bruce also has an operating partner for the US portfolio companies (CFO).

In 2002, he co-founded a Commodity Trading Advisor specializing in commodities and currencies. As its CFO, he executed a strategic partnership with SG Asset Management, Inc.

Later on, Bruce founded his own firm to provide advice to clients in a broad array of industries on matters from tax issues, strategic planning, and mergers & acquisitions.

Bruce holds a BS in accounting from Brooklyn College, CUNY. He obtained his CPA certificate in 1991 and is a member of the AICPA and NYSSCPA.

Independent board members

Per Wold-Olsen

CLOSE X

Per Wold-Olsen

Per Wold-Olsen was born on 6 November 1947 and is a Norwegian national. He holds an MBA in Economics Administration as well as an MBA in Management and Marketing.
Per Wold-Olsen joined Merck & Co. (MSD) in 1974. He became Managing Director of the Norwegian subsidiary in 1976 and Regional Director and Vice President of the Scandinavian region in 1986. In 1991, Per Wold-Olsen was appointed Senior Vice President for Worldwide Human Health Marketing of Merck & Co. Inc. in the US, and in 1994, he was appointed President of Human Health Europe of Merck & Co., Inc. In 1997, his region increased to include Eastern Europe, the Middle East and Africa, as well as Worldwide Human Health Marketing.

In 2005, he was appointed President of the Human Health Intercontinental Region, Merck & Co. Inc. From 1994 to 2006, he was also a member of Merck’s Management Committee.
Per Wold-Olsen is Chairman of the Board of Directors of GN Store Nord A/S, Denmark and Medicines for Malaria Venture, Switzerland, and serves on the Board of Directors of Gilead Sciences Inc., United States of America. He is also a board member of Novo Holdings since 2011.

Gilles Pagniez

CLOSE X

Gilles Pagniez

Gilles Pagniez is the Chief Executive Officer and partner of Temaris et Associés, an investment vehicle based in Paris. He was until February 2018, Deputy CEO of Group Artémis. Gilles has been involved during 25 years in numerous merger and acquisitions operations led by Group Artémis in a broad range of industries including luxury goods, insurance, real estate, construction, consumer goods and retail.

Gilles has served as a board member of many companies held by Group Artémis : Christie’s, an auction house; Château Latour, a premium vineyard; Le Ponant, a luxury cruise line; Le Point, a French magazine, Nextstage, a French investment Fund.

Gilles Initiated and participated in the creation of Red River Holding, a $250 million fund operating in Vietnam, which is the first fund set up by Artémis. He was member of the investment committee of the fund and within Artémis, responsible for the fund’s operations. He also participated in the creation of Red River Reinsurance Debt Purchase fund I and is member of the investment committee.

Gilles is graduated from Institut d’Etudes Politiques de Paris and holds a master in law from Paris Assas university.

Arié Assayag

CLOSE X

Arié Assayag

Arié Assayag is the Global CEO and co-CIO of Trajectoire Capital Group. Before founding the company in 2015, he was the CEO of UBP Alternative Investments based in Geneva, Switzerland (from 2012 to 2015), where he ran $10+bn of assets in funds of hedge funds and thematic funds (real estate, loans, insurance linked securities) in various formats. In 2009, he founded Nexar Capital Group (Paris/NYC) backed by the US Private Equity firm Acquiline. He grew the business to $3bn through both acquisitions (Allianz Alternative Investment & Ermitage) and organic growth before successfully selling the firm to UBP in 2012. From 1999 to 2009, Mr. Assayag was CEO of the Hedge Funds Unit at Société Générale AM (Paris) where he launched and grew the business to $12.4bn assets (more than $8bn in FoHF) and was awarded “Best Alternative Institutional House” by InvestHedge in 2005. From 1994 à 1999, he was a founding partner and Head of FX Derivatives at Commerzbank Financial Products, helping the bank become one of the global FX derivatives leaders. From 1985 to 1993, Arié worked for Société Générale where he launched and successfully developed several FX derivatives businesses (Tokyo & Chicago). Arié Assayag graduated from French top engineering school Ecole Centrale de Paris (ECP).

Laurent Bouyoux

CLOSE X

Laurent Bouyoux

Laurent Bouyoux is a Co-founder and Managing Partner of BlackFin Capital Partners. His expertise in the formation of companies can be dated to 1986 when he becomes one of the founders of the Société Générale’s derivatives business, in Paris and Tokyo. 5 years later, Laurent becomes Deputy Head of Global Derivatives (then Global Fixed Income of Société Générale) until 1994. In that same year, he joins Commerzbank group in Frankfurt, and alongside Paul Mizrahi, becomes a founder and shareholder of Commerz Financial Products, a subsidiary created to develop Commerzbank’s derivatives business in Europe.

In 1999, alongside Paul Mizrahi and Eric May, Laurent founds the ProCapital group, a regulated investment firm and member of Euronext, and acts as Executive. Chairman of the Management Board. ProCapital was involved in two businesses, securities services and, through its subsidiary Fortuneo, online brokage. They grew the business to become the French leader in the sector, combining organic growth and a number of targeted acquisitions. The founders sold ProCapital (including Fortuneo) in 2006, and until 2008 Laurent Bouyoux worked for Aquiline Capital Partners in New York, a leading US private equity firm specializing in the financial services sector, as a Senior Principal.
A French national, Laurent is graduate of the Ecole Polytechnique and the Ecole de la Statistique et de l’Administration Economique (ENSAE).

David Norton

CLOSE X

David Norton

Mr. Norton was previously Company Group Chairman, Global Pharmaceuticals, for Johnson & Johnson, a role in which he led and developed the business’ strategic growth agenda, including the strategy for licensing, acquisitions and divestments, and ensuring alignment with the global strategic functions, research and development, and commercial organizations. His 32-year tenure at Johnson & Johnson spanned marketing and country management roles across Belgium, Australia and New Zealand; and serving as president of the Janssen Pharmaceutica business in the U.S., group chairman of the Pharmaceuticals Group for Europe, Middle East and Africa, and then for the U.S. and Canada business, as well as company group chairman, worldwide commercial and operations, for Johnson & Johnson’s CNS and virology business. He is currently chairman of the board of directors of VIVUS, Inc., and also serves on the board of TB Alliance, a not-for-profit organization dedicated to the discovery and development of better, faster-acting and affordable tuberculosis drugs that are available to those who need them. He previously served as a director for INC Research Holdings Inc. and Savient Pharmaceuticals Inc.

Geoff Kalish

CLOSE X

Geoff Kalish

Geoff joined Aquiline in 2005. He is a partner and is the chief operating officer of the firm. Prior to joining Aquiline, he was with Venturion Capital, a private equity firm he co-founded that invested in financial services companies in North America and Europe. Previously, he led the European financial services investment banking practice of Smith Barney and was a senior manager of its global financial services capital markets practice. Earlier in his career, as a venture capitalist, he founded three start-up companies and served as a proprietary trader of exchange rate and interest rate products for Drexel Burnham Lambert, Kidder Peabody and Westpac Bank.

Geoff’s current investments include FIFS and Virtus. He previously worked with BinckBank, BISAM, Fenergo, CRT, Nexar, and Structured Credit Holdings.

Geoff holds a B.A. in History, from Columbia University and a Masters of Public Policy in International Finance from John F. Kennedy School of Government at Harvard University.

Dr. Philippe Schaison

CLOSE X

Dr. Philippe Schaison

Dr. Schaison is a CEO, CCO and Global President in consumer healthcare, consumer goods & retail sectors with experience running a $2.5B+ business growing 17% a year (Allergan), acquiring/integrating a +$2B organization, and successfully leading global organizations. Hired by the Chairman & Board of Directors of Syneron-Candela NA (Irvine, CA), to take a publicly traded company (ELOS) private, Dr. Schaison sold the company to Private Equity firm Apax in July 2017 for $11 a share; a two-fold increase over past trading value (Nov 2016 – $6 a share). Earlier, as Allergan President, US Aesthetic & Dermatology, Dr. Schaison led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business units. He enabled the organic growth of the $2.5B business by 17% a year and acquired Kythera for $2.1B.

Before, Dr. Schaison was President, Clarins WW Travel Retail & Regional President, LATAM and MEA, leading a $1B+ business, he generated 55% of Clarins’ total net sales & 70% of its EBIT, achieving 28% growth in a single digit market. Earlier, Dr. Schaison served as CEO for Aesthetic Factors.

As VP, Global Skin Care for Johnson & Johnson, with P&L responsibility for leading brands and a Board Member, Ortho- Neutrogena.
Dr. Schaison earned an MBA from the Hautes Etudes Commerciales, and a Doctorate in Pharmacy from the University Of Paris V.